Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AdaptHealth (AHCO) Gains from Sales and Divestitures (2020 - 2022)

Historic Gains from Sales and Divestitures for AdaptHealth (AHCO) over the last 3 years, with Q3 2022 value amounting to $461000.0.

  • AdaptHealth's Gains from Sales and Divestitures rose 3761.19% to $461000.0 in Q3 2022 from the same period last year, while for Sep 2022 it was $461000.0, marking a year-over-year increase of 3761.19%. This contributed to the annual value of $556000.0 for FY2021, which is 277.26% up from last year.
  • According to the latest figures from Q3 2022, AdaptHealth's Gains from Sales and Divestitures is $461000.0, which was up 3761.19% from $350000.0 recorded in Q2 2022.
  • AdaptHealth's 5-year Gains from Sales and Divestitures high stood at $556000.0 for Q4 2021, and its period low was $15417.0 during Q1 2020.
  • Over the past 3 years, AdaptHealth's median Gains from Sales and Divestitures value was $230000.0 (recorded in 2022), while the average stood at $257037.9.
  • Examining YoY changes over the last 5 years, AdaptHealth's Gains from Sales and Divestitures showed a top increase of 68000.0% in 2021 and a maximum decrease of 277.26% in 2021.
  • Quarter analysis of 3 years shows AdaptHealth's Gains from Sales and Divestitures stood at $541000.0 in 2020, then grew by 2.77% to $556000.0 in 2021, then dropped by 17.09% to $461000.0 in 2022.
  • Its Gains from Sales and Divestitures was $461000.0 in Q3 2022, compared to $350000.0 in Q2 2022 and $230000.0 in Q1 2022.